Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap
Either ESR1-positive and/or ESR2-low pT1 tumors.Introduction Estrogens influence the aggressiveness of breast cancer through their cognate nuclear receptors. In particular, the estrogen receptor-alpha (ERa) (ESR1) - present in tumor cells of about 70 to 75 of all breast tumors is considered crucial because of its proliferationinducing actions and for that reason is an important target for therap
Ltivariable analyses, increasing levels of DC-SCRIPT were associated with good prognosis only for pT1 (small tumor without lymphatic/vascular invasion) tumors and not for larger tumors. These and additional exploratory Cox univariate analyses are summarized in Table 3. The prognostic value of DC-SCRIPT is visualized in KaplanMeier curves (Figure 1) as a dichotomized variable in these biologically
Ltivariable analyses, increasing levels of DC-SCRIPT were associated with good prognosis only for pT1 (small tumor without lymphatic/vascular invasion) tumors and not for larger tumors. These and additional exploratory Cox univariate analyses are summarized in Table 3. The prognostic value of DC-SCRIPT is visualized in KaplanMeier curves (Figure 1) as a dichotomized variable in these biologically
Their advanced disease and therefore was better suited to study a putative relation of DC-SCRIPT and response to therapy. Despite the positive association of DC-SCRIPT with ESR1, DC-SCRIPT levels were unable to identify patients with ESR1-positive primary tumors at high or low risk to progress if treated with tamoxifen. Thus, although DC-SCRIPT can modulate the activity of ESR1, it does not affect
Their advanced disease and therefore was better suited to study a putative relation of DC-SCRIPT and response to therapy. Despite the positive association of DC-SCRIPT with ESR1, DC-SCRIPT levels were unable to identify patients with ESR1-positive primary tumors at high or low risk to progress if treated with tamoxifen. Thus, although DC-SCRIPT can modulate the activity of ESR1, it does not affect
Nally, stromal cells may have played a role in the induction of DC-SCRIPT in the epithelial tumor cells. In analogy, ESR2 is - apart from breast cancer epithelial tumor cells - also expressed in adjacent infiltrating lymphocytes, fibroblasts, and endothelial cells [3]. Interestingly, in tumors that express relatively high ESR2 mRNA levels and that in general have a higher stromal content, DC-SCRIP
Provide blood samples at the National Cancer Center Hospital, Korea, between April 2001 and December 2004. Among a total of 856 cases considered for the initial recruitment, 747 patients remained eligible after exclusion for the following: (1) distant metastasis at diagnosis (8 cases), (2) ductal carcinoma in situ (70 cases), (3) cancer with unreported ER/PR status (29 cases), (4) male gender (1 c